

## Quick Facts

Website: [www.organovo.com](http://www.organovo.com)  
Headquarters: San Diego, CA, USA  
Founded: 2007  
Employees: 115+ globally  
Fiscal 2016 Revenue: \$1.5 million

## Stock Information

Ticker Symbol: ONVO  
Stock Exchange: NASDAQ  
Shares Outstanding: 104.4 million  
Insider Ownership: 13%  
Investor Relations: [ir@organovo.com](mailto:ir@organovo.com)

## Management Team

### Taylor J. Crouch

Chief Executive Officer

### Craig Kussman

Chief Financial Officer

### Sharon Collins Presnell, Ph.D.

Chief Scientific Officer

### Susan Daugherty

Senior Vice President, Human Resources

### Eric Michael David, M.D., J.D.

Chief Strategy Officer and  
EVP, Preclinical Development

### Paul Gallant

General Manager, Commercial Operations

### Jennifer Kinsbruner Bush, J.D.

General Counsel and Corporate Secretary

## About Organovo

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company's ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications.

## Our Vision and Business

**We're changing the shape of life science research and transforming medical care.** Our goal is to address the gaps that exist in pharmaceutical discovery and significantly impact the cost, predictability and speed of drug development. We provide superior predictive solutions that recreate 3D native tissue architecture, which allows our customers to de-risk their drug discovery programs by enabling decisions points further upstream. We also have the potential to revolutionize therapeutic applications by creating tissue replacement products for surgical implantation, addressing the dramatic supply issues that are a constant challenge in transplant medicine.

## Investment Highlights

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong intellectual property (IP) portfolio
- We expect to grow revenue by building a robust product and service platform



© 2017 Organovo Holdings, Inc. All rights reserved. Current as of 11 May 2017

Any statements contained in this fact sheet that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the market acceptance of the Company's products and services; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships; the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all. These and other factors are identified and described in more detail in the Company's filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.